Literature DB >> 2551488

Lack of drug-induced DNA cross-links in chlorambucil-resistant Chinese hamster ovary cells.

B Z Jiang1, B B Bank, Y H Hsiang, T Shen, M Potmesil, R Silber.   

Abstract

Chlorambucil (CLB) is an alkylating agent commonly used in the treatment of several neoplastic disorders. The mechanisms underlying resistance to this drug are not fully defined. We used the DNA alkaline elution technique to study cross-link formation in the wild type (K1) and a CLB-resistant (ChlR) Chinese hamster ovary cell line. [14C]CLB was used to measure drug uptake. The CLB-resistant cells were found to have negligible DNA cross-link formation compared to K1 cells at all time points tested. There was a correlation between the resistance to CLB and the decreased ability of resistant cells to form DNA cross-links. Results of drug uptake experiments excluded altered CLB accumulation as the basis for these findings. Assays of O6-alkylguanine transferase and topoisomerase. II provide evidence against a role of these enzymes in CLB resistance. These studies suggest that the mechanism of CLB cytotoxicity involves the formation of DNA cross-links. Reduced cross-link formation may confer resistance to CLB.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2551488

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

Review 1.  Resistance to cytostatic drugs at the cellular level.

Authors:  C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Role of DNA repair in the mechanisms of cell resistance to alkylating agents and cisplatin.

Authors:  P Calsou; B Salles
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Nitrogen mustard-DNA interaction in melphalan-resistant mammary carcinoma cells with elevated intracellular glutathione and glutathione-S-transferase activity.

Authors:  M A Alaoui-Jamali; L Panasci; G M Centurioni; R Schecter; S Lehnert; G Batist
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro.

Authors:  S R Wedge; J K Porteus; B L May; E S Newlands
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

5.  3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.

Authors:  S R Wedge; J K Porteous; E S Newlands
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.